Giant Biogene Holding Co., Ltd.
2367
Category
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 11.44 | -29.95% |
| 2025 | 16.33 | -28.20% |
| 2024 | 22.75 | 4.38% |
| 2023 | 21.80 | -24.58% |
| 2022 | 28.90 | 12.90% |
| 2021 | 25.60 | -5.03% |
| 2020 | 26.95 | -37.07% |
| 2019 | 42.83 | 0.00% |
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 23.20 | 102.77% |
US
|
|
| 32.48 | 183.94% |
FR
|
|
| 36.71 | 220.94% |
US
|
|
| 29.80 | 160.53% |
IN
|
|
| 203.25 | 1,676.78% |
US
|
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.